Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cutaneous manifestations of Epstein-Barr virus (EBV)-driven B-cell lymphoid proliferations occur rarely as a result of severe immunodeficiency. To date, only a few cases of extranodal EBV-associated B-cell lymphomas arising in patients with angioimmunoblastic T-cell lymphoma (AITL) have been reported, and less common is a cutaneous presentation. AITL is a rare aggressive tumor that carries a poor prognosis and prompt diagnosis, and recognition of EBV-associated diffuse B-cell lymphoma is essential in these patients to instigate the correct treatment.

Original publication

DOI

10.1097/DAD.0000000000001371

Type

Journal

Am J Dermatopathol

Publication Date

12/2019

Volume

41

Pages

927 - 930

Keywords

Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Humans, Immunoblastic Lymphadenopathy, Immunocompromised Host, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Male, Middle Aged, Prednisone, Skin Neoplasms, Treatment Outcome, Vincristine, Virus Replication